For research use only. Not for use in humans.

Anti-CXCL8 / IL-8 (HuMax-IL8)

Synonyms: IL-1RL2， IL-36R Cat.No.A2670 Purity:99%

Anti-CXCL8 / IL-8 (HuMax-IL8) is a monoclonal antibody targeting CXCL8. It has strong antitumor effect. MW :144.94 KD.

Quality Control

Batch: A267001 Purity: 99% Protein concentration: 5.17mg/ml Endotoxin Level: ＜1EU/mg

Cited in Nature Medicine for its top-tier quality
COA
SDS
Datasheet

Featured Inhibitors	Y-27632 Dihydrochloride SB431542 CHIR-99021 (Laduviglusib) RMC-7977 RMC-6236 (Daraxonrasib) MRTX1133 MG132 Z-VAD-FMK VT3989 IAG933

Specificity

Name	Citation	CXCR1	CXCR2	CXCR4	CXCR3	Others
WZ811	21			++++
Mavorixafor	0			+
AMG 487	4				+++
Motixafortide (BL-8040, BKT140)	1			++++		cyclin-D1,MCL-1,Bcl-2
Navarixin (SCH-527123)	9	++	+++
MSX-122	1			+++
LY2510924	2			++++
Reparixin (Repertaxin)	26	++++	+			CXCL8
SB 225002	91		++
Ladarixin	0	✔
SB 265610	4		✔
Balixafortide (POL6326)	1			✔
SX-682	4	✔
TAK-779	0				✔	CCR5
MSX-130	0			✔
MSX-127	0			✔
AZD5069	6		✔
Danirixin (GSK1325756)	2		✔			CXCL8
LIT-927	8			✔		CXCL12
AMD3465 hexahydrobromide	1			✔

Expand to Check More

1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description	Anti-CXCL8 / IL-8 (HuMax-IL8) is a monoclonal antibody targeting CXCL8. It has strong antitumor effect. MW :144.94 KD.
References	[1] https://pubmed.ncbi.nlm.nih.gov/35011369/

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID

Product Details

Molecular Weight	144.94
Isotype	Human IgG1
Source	CHO
Purification	AKTA
Sterility	0.2 μM filtered
Formulation	100 mM Pro-Ac, 20mM Arg, pH5.0
Storage (From the date of receipt)	Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

^*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04848116	ACTIVE_NOT_RECRUITING	Drug: Nivolumab\|Drug: HuMax-IL8	Head and Neck Squamous Cell Carcinoma	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	2021-04-24	PHASE2
NCT02536469	COMPLETED	Drug: HuMax-IL8	Solid Tumor	Bristol-Myers Squibb	2015-08	PHASE1

(data from https://clinicaltrials.gov, updated on 2026-05-14)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.